153 related articles for article (PubMed ID: 14697909)
1. Patient persistency with topical ocular hypotensive therapy in a managed care population.
Reardon G; Schwartz GF; Mozaffari E
Am J Ophthalmol; 2004 Jan; 137(1 Suppl):S3-12. PubMed ID: 14697909
[TBL] [Abstract][Full Text] [Related]
2. Persistency with latanoprost or timolol in primary open-angle glaucoma suspects.
Schwartz GF; Reardon G; Mozaffari E
Am J Ophthalmol; 2004 Jan; 137(1 Suppl):S13-6. PubMed ID: 14697910
[TBL] [Abstract][Full Text] [Related]
3. Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study.
Reardon G; Schwartz GF; Mozaffari E
Clin Ther; 2003 Apr; 25(4):1172-85. PubMed ID: 12809964
[TBL] [Abstract][Full Text] [Related]
4. Patient persistency with pharmacotherapy in the management of glaucoma.
Reardon G; Schwartz GF; Mozaffari E
Eur J Ophthalmol; 2003 Jul; 13 Suppl 4():S44-52. PubMed ID: 12948052
[TBL] [Abstract][Full Text] [Related]
5. Observed time between prescription refills for newer ocular hypotensive agents: the effect of bottle size.
Platt R; Reardon G; Mozaffari E
Am J Ophthalmol; 2004 Jan; 137(1 Suppl):S17-23. PubMed ID: 14697911
[TBL] [Abstract][Full Text] [Related]
6. Discontinuation rates of topical glaucoma medications in a managed care population.
Shaya FT; Mullins CD; Wong W; Cho J
Am J Manag Care; 2002 Aug; 8(10 Suppl):S271-7. PubMed ID: 12188170
[TBL] [Abstract][Full Text] [Related]
7. Topical prostaglandin fixed combinations in UK primary care: observational study using data from the health improvement network.
Loftus J; Christopoulou D; Blak BT; Hards M
Eur J Ophthalmol; 2012; 22(3):376-87. PubMed ID: 22034021
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
Stewart WC; Konstas AG; Nelson LA; Kruft B
Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
[TBL] [Abstract][Full Text] [Related]
9. Accounting for restart rates in evaluating persistence with ocular hypotensives.
Schwartz GF; Platt R; Reardon G; Mychaskiw MA
Ophthalmology; 2007 Apr; 114(4):648-52. PubMed ID: 17398318
[TBL] [Abstract][Full Text] [Related]
10. Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data.
Dasgupta S; Oates V; Bookhart BK; Vaziri B; Schwartz GF; Mozaffari E
Am J Manag Care; 2002 Aug; 8(10 Suppl):S255-61. PubMed ID: 12188168
[TBL] [Abstract][Full Text] [Related]
11. Rates of discontinuation and change of glaucoma therapy in a managed care setting.
Spooner JJ; Bullano MF; Ikeda LI; Cockerham TR; Waugh WJ; Johnson T; Mozaffari E
Am J Manag Care; 2002 Aug; 8(10 Suppl):S262-70. PubMed ID: 12188169
[TBL] [Abstract][Full Text] [Related]
12. Hyperemia-associated costs of medication changes in glaucoma patients treated initially with prostaglandin analogs.
Schwartz GF; Tan J; Kotak S
J Ocul Pharmacol Ther; 2009 Dec; 25(6):555-61. PubMed ID: 20028264
[TBL] [Abstract][Full Text] [Related]
13. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy?
Robin AL; Covert D
Ophthalmology; 2005 May; 112(5):863-8. PubMed ID: 15878067
[TBL] [Abstract][Full Text] [Related]
14. Latanoprost : an update of its use in glaucoma and ocular hypertension.
Perry CM; McGavin JK; Culy CR; Ibbotson T
Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
[TBL] [Abstract][Full Text] [Related]
15. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma.
Quaranta L; Gandolfo F; Turano R; Rovida F; Pizzolante T; Musig A; Gandolfo E
Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):2917-23. PubMed ID: 16799034
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
[TBL] [Abstract][Full Text] [Related]
17. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA
Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
García-López A; Paczka JA; Jiménez-Román J; Hartleben C
BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
[TBL] [Abstract][Full Text] [Related]
19. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
Easthope SE; Perry CM
Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
[TBL] [Abstract][Full Text] [Related]
20. Persistency rates for prostaglandin and other hypotensive eyedrops: population-based study using pharmacy claims data.
Rait JL; Adena MA
Clin Exp Ophthalmol; 2007; 35(7):602-11. PubMed ID: 17894679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
